Both allow FSA/HSA use in many cases
Key terms include: $150 million upfront payment to Yao Pharma Up to $1.935 billion in development, regulatory, and commercial milestone payments Tiered royalties on future global sales Coverage across all therapeutic, diagnostic, and prophylactic indications for both human and veterinary use This structure positions the agreement as one of the larger oral-GLP-1 licensing deals in recent years
Ready to discover which peptide stack is right for you
Boxed warning thyroid C-cell tumors: GLP-1-based medications (including semaglutide and tirzepatide) carry an FDA boxed warning for thyroid C-cell tumors observed in rodent studies
It favors small, frequent sips over large volumes at once, and notes many patients tolerate room-temperature or slightly warm water better than cold, which can worsen nausea
Around 15.5 million people, or 6% of adults in the U.S., say theyve tried GPL-1 weight loss drugs, according to a Gallup poll